Pathology: metastatic/advanced OC (mOC) - 1st line (L1); metastatic/advanced OC (mOC) - 2nd line (L2); metastatic/advanced OC (mOC) - maintenance (M); mOC - L1 - all population; mOC - L1 - PDL1 positive;
| metastatic/advanced OC (mOC) - 1st line (L1) | metastatic/advanced OC (mOC) - 2nd line (L2) | metastatic/advanced OC (mOC) - maintenance (M) | mOC - L1 - all population | mOC - L1 - PDL1 positive | |||||
| AGO-OVAR 2.29/ENGOT-ov34, 2024 | JAVELIN ovarian 200 (A vs doxorubicin), 2021 | JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 | NRG GY003, 2020 | JAVELIN Ovarian 100, 0 | ATHENA-COMBO (GOG-3020/ENGOT-ov45), 2021 | IMagyn-050 (all population), 2021 | IMagyn-050 (PDL1 >1%), 2021 | ||
| atezolizumab plus SoC | 2 | T1 | T1 | ||||||
| atezolizumab plus bevacizumab plus carboplatin plus paclitaxel | 1 | T1 | |||||||
| avelumab plus SoC | 1 | T1 | |||||||
| avelumab alone | 1 | T1 | |||||||
| avelumab plus pegylated liposomal doxorubicin | 1 | T1 | |||||||
| nivolumab based treatment | 1 | T1 | |||||||
| nivolumab plus ipilimumab | 1 | T1 | |||||||
| bevacizumab plus carboplatin and paclitaxel | 0 | T0 | |||||||
| Standard of Care (SoC) | 0 | T0 | |||||||
| pegylated liposomal doxorubicin | 0 | T0 | T0 | ||||||
| rucaparib | 0 | T0 | |||||||
| placebo plus SoC | 0 | T0 | T0 | ||||||
| nivolumab alone | 0 | T0 | |||||||